Navidea Biopharmaceuticals Announces Additional Results from Lymphoseek® Phase 3 Clinical Trial in Head and Neck Cancer at American College of Surgeons 2013 Annual Clinical Congress Oct 7, 2013
Navidea Biopharmaceuticals to Present at BioCentury’s NewsMakers in the Biotech Industry Conference Sep 24, 2013
Navidea Biopharmaceuticals Completes $30 Million Registered Direct Offering of Common Stock Sep 24, 2013
Independent Investigators Report Lymphoseek® Results in JAMA Otolaryngology Head and Neck Surgery Sep 19, 2013
Navidea Biopharmaceuticals Presents New Data on Precision Diagnostic Platform at Harvard Conference Sep 19, 2013
Navidea Awarded an Additional NIH SBIR Grant for NAV4694 Beta-Amyloid Imaging Agent for Study in Mild Cognitive Impairment Sep 4, 2013
Navidea Biopharmaceuticals Announces Agreement with FDA on Special Protocol Assessments for NAV5001 Phase 3 Program Aug 22, 2013
Navidea Awarded NIH SBIR Grant for NAV4694 Beta-Amyloid Imaging Agent Phase 3 Clinical Program Aimed at Alzheimer’s Disease Aug 21, 2013
Navidea Biopharmaceuticals Signs Manufacturing Agreement with Siemens’ PETNET Solutions for NAV4694 Beta-amyloid Imaging Agent Aug 21, 2013
Navidea Biopharmaceuticals Announces Centers for Medicare & Medicaid Services (CMS) Issuance of Lymphoseek® Reimbursement Pass-Through C Code, Effective as of October 1, 2013 Aug 20, 2013
